What Maxor does

Maxor, doing business as VytlOne, is a privately held, US-based pharmacy services and pharmacy benefit management (PBM) company headquartered in Amarillo, Texas. Following its January 2025 strategic combination with ProxsysRx, Maxor/VytlOne is positioned as the largest independent provider of integrated pharmacy management services to health systems, hospitals, and clinics. The company serves six customer segments — health systems and hospitals, health centers, employers and health plans, brokers and consultants, payers, and pharmaceutical manufacturers — and delivers end-to-end capabilities spanning managed pharmacy solutions, PBM plan design and administration, specialty and rare-disease pharmacy, and 340B program optimization.

The product portfolio includes VytlAIQ, an end-to-end AI platform marketed as providing intelligent pharmacy orchestration for 340B and specialty pharmacy operations, alongside core services in retail and specialty pharmacy management, PBM solutions, and manufacturer/payer support services. Maxor reports a 70% average capture rate and a 42% average increase in new 340B savings capture for partners, and cites $1.3B in revenue returned to partners in 2024 via its pharmacy management platform. The company holds multiple accreditations, including URAC Specialty Pharmacy, URAC Mail Service Pharmacy, URAC PBM, The Joint Commission National Quality Approval for specialty pharmacy, and ACHC certification.

Maxor generates revenue through a managed-services model, with pricing delivered via quote-based enterprise contracts rather than disclosed rates. The go-to-market motion is enterprise field sales supplemented by a broker/consultant channel for employer accounts. Mike Ellis, who led the company since 2016, transitioned to Chairman of the Board in January 2025; Kim Tzoumakas was appointed CEO effective January 6, 2025, and ProxsysRx's former CEO George Salem joined as Board Observer concurrent with the merger. No parent company or public-market listing is reported.

Name

Maxor

Legal name

Maxor

Website

https://maxor.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Maxor, operating as VytlOne, is the largest independent US provider of integrated pharmacy management and PBM services to health systems, hospitals, health centers, employers, health plans, payers, and pharmaceutical manufacturers, with proprietary AI platform VytlAIQ for 340B and specialty pharmacy.

Ownership category

akta.pro rank

Product category

Pharmacy Benefit Management

NAICS

Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292), Pharmacies and Drug Retailers (456110)

SIC

Services-Health Services (8000), Retail-Drug Stores And Proprietary Stores (5912)

akta.pro primary industry

340B Program Administration & Contract Pharmacy Services (HLAFALAL)

akta.pro secondary industries

Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops) (CRAOAHAK), Formulary Management & Clinical Pharmacy Programs (HLAEAKAA), Pharmacy Benefit Management (PBM) & Formulary Management IT (HLACAKAD)

Keywords

• Pharmacy benefit management
• Specialty pharmacy services
• 340B program optimization
• Rare disease pharmacy
• Pharmacy analytics software

Headquarters

HQ city

Plano

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmacy Management Services: Maxor/VytlOne provides integrated pharmacy management services to health systems, hospitals, clinics, and health centers. The company generates revenue through specialty and retail pharmacy management, 340B optimization, PBM solutions, and manufacturer and payer support services. As the largest independent provider of pharmacy management services following the strategic combination with ProxsysRx, the company helps partners unlock pharmacy revenue and delivers $1.3B in revenue back to partners.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Core offering

Maxor provides pharmacy benefit management (PBM), specialty and rare disease pharmacy, 340B optimization, and AI-driven pharmacy analytics (via VytlAIQ) to health systems, hospitals, health centers, employers, health plans, and pharmaceutical manufacturers. The company operates as VytlOne and combines clinical pharmacy programs with technology-enabled managed pharmacy solutions.

Product overview

Maxor operates under the VytlOne brand as the only independent provider of integrated pharmacy solutions. The company offers a unified portfolio combining PBM and pharmacy services into one integrated platform. Key offerings include VytlAIQ (an AI-powered platform for 340B and specialty pharmacy orchestration), Managed Pharmacy Solutions, Pharmacy Benefit Management, Rare Disease and Specialty Pharmacy, 340B Optimization, and manufacturer/payer support services. Following the strategic combination with ProxsysRx, the merged entity represents the largest independent provider of pharmacy management services to health systems, hospitals, and clinics, offering end-to-end capabilities across specialty and retail pharmacy management.

Differentiator

Problem solved

Functional benefit

Brands

• VytlAIQ: The end-to-end AI platform for 340B and specialty pharmacy.

Products and services

• Pharmacy Benefit Management (PBM) End-to-end pharmacy benefit management services including benefit design, claims processing, formulary management, medication therapy management, and clinical programs for health systems, employers, and health plans.
• Specialty and Rare Disease Pharmacy Specialty and rare disease pharmacy dispensing and clinical management services for complex, high-cost therapies, supporting patients, providers, manufacturers, and payers.
• 340B Program Optimization Consultative and operational services to help hospitals, health centers, and other covered entities maximize 340B program savings, maintain compliance, and capture pharmacy revenue.
• Managed Pharmacy Solutions Operational pharmacy management for hospitals and health systems, including consolidated pharmacy centers and on-site pharmacy management solutions enabled through the ProxsysRx combination.
• VytlAIQ Proprietary AI-powered analytics platform for 340B program optimization, specialty pharmacy performance, and clinical decision support, available to Maxor clients and partners.
• Manufacturer and Payer Support Services Distribution, patient access, hub, and support services for pharmaceutical manufacturers and payers managing specialty and rare disease therapies.

Quantifiable outcome

• 70% average capture rate for 340B optimization
• +2 more outcomes

Segments6 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature1 record

Partnerships

One partnership is on record.

• ProxsysRxcoreStrategic or Co-development Partner · 6 January 2025Strategic combination announced January 2025, creating the largest independent provider of pharmacy management services to health systems, hospitals, and clinics. The merged entity offers end-to-end capabilities across specialty and retail pharmacy management, 340B optimization, PBM solutions, and manufacturer and payer support services. ProxsysRx CEO George Salem moved to a Board Observer role in the combined company.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Shields Health Solutions: Specialty pharmacy management company partnered with health systems to launch and operate specialty pharmacy programs — directly overlapping with Maxor/VytlOne's specialty pharmacy and 340B-optimized managed pharmacy solutions for hospital clients.
• Trellis Rx: Specialty pharmacy services company that partners with health systems to build and operate specialty pharmacy programs — directly comparable to Maxor/VytlOne's specialty and rare-disease pharmacy offering.
• Comprehensive Pharmacy Services (CPS): One of the largest U.S. providers of hospital pharmacy management and consulting services — a direct competitor to Maxor's managed pharmacy solutions across health systems and hospitals.
• Aprexis Health Solutions: 340B program administration and specialty pharmacy operator serving health systems and federally qualified health centers — directly competes with Maxor's 340B optimization and contract pharmacy services.

Broad incumbents

• OptumRx (UnitedHealth Group): Largest U.S. PBM by prescription volume and embedded inside UnitedHealthcare; competes with Maxor's PBM solutions and is increasingly expanding into health-system specialty pharmacy through Optum acquisitions.
• PharMerica (BrightSpring Health Services): Long-term care, specialty, and institutional pharmacy operator — overlaps with Maxor's specialty pharmacy management capabilities and serves similar health-system and post-acute customers.
• CVS Health (Caremark / Cordavis): Operates Caremark, the largest U.S. PBM, alongside retail/specialty pharmacy; increasingly offers hospital and health-system pharmacy services — a broad incumbent competing across Maxor's PBM and pharmacy services lines.
• Walgreens Boots Alliance (VillageMD / Shields): Owns Shields Health Solutions and operates a large specialty and retail pharmacy footprint; competes with Maxor in health-system specialty pharmacy and 340B contract pharmacy arrangements.
• Express Scripts (Cigna / Evernorth): Top-3 U.S. PBM operating inside Evernorth; offers specialty pharmacy, formulary management, and 340B-adjacent services — competing broad incumbent to Maxor's integrated pharmacy offering.

Emerging players

• PSG Consulting / 340Basics: Independent 340B program administrator and consulting firm targeting community health centers and hospitals — a smaller-scale alternative to Maxor's 340B Optimization offering.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maxor